Bio

Greg Sargen is an operating partner at Altaris and chair of the audit committee at Kindeva Drug Delivery and Veranova. Greg has over twenty-five years of experience in the pharmaceutical services industry and has served on the board of two publicly traded biopharmaceutical companies. Previously, Mr. Sargen was Executive Vice President and Chief Financial Officer, and Vice President of Corporate Development and Strategy at Cambrex Corporation, a publicly traded Contract Development and Manufacturing Organization. Mr. Sargen also held finance roles at Fisher Scientific International (now ThermoFisher), Merck & Co and Expanets. Mr. Sargen began his career in auditing at Deloitte & Touche, LLP, and is a Certified Public Accountant. Mr. Sargen holds a B.S. in Accounting from Penn State University and an MBA from The Wharton School.